Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. Abstract Text:

Shaun K Rodriguez,Abdoulaye Dieng Sarr,Adam MacNeil,Seema Thakore-Meloni,Aissatou Gueye-Ndiaye,Ibrahima ,Mamadou C Dia,Souleymane Mboup,Phyllis J Kanki,

Neutralizing antibody responses against heterologous isolates in human immunodeficiency virus type 1 (HIV-1) and HIV-2 infections were compared, and their relationships with established clinical markers of progression were examined. Neutralizing responses against 7 heterologous primary isolates and 1 laboratory strain were compared between 32 untreated HIV-1-infected subjects and 35 untreated HIV-2-infected subjects using a pseudotyped reporter virus assay. The breadth of the neutralizing response, defined as the proportion of panel viruses positively neutralized by patient plasma, was significantly greater among HIV-2-infected subjects than among HIV-1-infected subjects. Notably, for fully one-third of HIV-2 subjects, all viruses were effectively neutralized in our panel. Magnitudes of responses, defined as reciprocal 50% inhibitory concentration (IC(50)) titers for positive reactions, were significantly greater among HIV-1-infected subjects than among HIV-2-infected subjects. When plasma samples from HIV-1 patients were tested for cross-neutralization of HIV-2 and vice versa, we found that these intertype responses are very rare and their prevalences comparable in both HIV-1 and HIV-2 infection. The significantly higher magnitude of heterologous responses for HIV-1 compared to HIV-2 prompted us to examine associations with viremia, which is known to be significantly higher in HIV-1 infection. Importantly, there was a significant positive correlation between the IC(50) titer and viral load within both the HIV-1 and HIV-2 groups, suggesting heterologous antibodies may be driven by viral replication. We conclude that HIV-2 infection is characterized by a broad, low-magnitude intratype neutralization response, while HIV-1 is characterized by a narrower but higher-magnitude intratype response and that a significant positive association between the IC(50) titer and viremia is common to both HIV-1 and HIV-2 infections.

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. Publishing Authors By Initials

SK Rodriguez,AD Sarr,A MacNeil,S Thakore-Meloni,A Gueye-Ndiaye,I ,MC Dia,S Mboup,PJ Kanki,

For similar virus diseases: viremia research abstracts see: virus diseases: viremia research

PUBMED ID PMID:

MEDLINE DATE:

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of virology

VOLUME: 81

Page Numbers: 5331-8

Journal Abbreviation:

ISSN: 0022-538X

DAY: 14

MONTH: 02

YEAR: 2007

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 113724

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. Keywords Mesh Terms:

KEYWORDS: Viremia

MESH TERMS: immunology

Chemical & Substance for Abstract: Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. Information

Substance Name: HIV Antibodies

Registry Number: 0

Grant and Affiliation Information for Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.

AFFILIATION: Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA.

Country: United States

AGENCY: United States NIAID

GRANT: AI46274-04

ACRONYM: AI

MEDLINETA: J Virol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 HIV-1- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections Related Publications

• Characterization of HIV Type 1 Reverse Transcriptase Mutations in Infants Infected by Mothers Who Received Peripartum Nevirapine Prophylaxis in Jos, Nigeria.
• Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
• Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.
• Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective.
• Interplay of Reverse Transcriptase Inhibitor Therapy and Gag p6 Diversity in HIV Type 1 Subtype G and CRF02_AG.
• Long-term intrapatient viral evolution during HIV-2 infection.
• Partner disclosure of HIV status among HIV positive mothers in Northern Nigeria.
• Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients.
• Relationship between Human Immunodeficiency Type 1 Infection and Expression of Human APOBEC3G and APOBEC3F.
• The Level of APOBEC3G (hA3G)-Related G-to-A Mutations Does Not Correlate with Viral Load in HIV Type 1-Infected Individuals.
• The complexity of circulating HIV type 1 strains in Oyo state, Nigeria.
• Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity.